Overview

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
To assess the single dose pharmacokinetics (PK) of celecoxib in healthy subjects when administered alone and following multiple daily doses of AKB-6548.
Phase:
Phase 1
Details
Lead Sponsor:
Akebia Therapeutics
Treatments:
Celecoxib